- December 14, 2021– Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments…
- December 9, 2021NEW YORK, December 9, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- November 23, 2021NEW YORK, November 23, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- November 18, 2021NEW YORK, November 18, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- November 4, 2021– Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – – Initiated Phase 2 CALLIPER Trial…
- November 1, 2021– Webcast to be Held at 8:00 am ET on November 4, 2021 – NEW YORK, November 1, 2021 – Immunic,…
- October 28, 2021– Top-Line Data Expected in the Second Quarter of 2022 – NEW YORK, October 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a…
- October 27, 2021– Represents the First Time Patients Will Be Treated With the Company’s Potentially Best-In-Class RORγt Inverse Agonist – NEW YORK,…
- October 14, 2021NEW YORK, October 14, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- September 30, 2021NEW YORK, September 30, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
